Compare Amphastar Pharmaceuticals Inc (AMPH) vs NIO Inc. (NIO) Price & Performance

AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.

Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.

NIO trades at $4.74, up 3.04% today but remains under pressure with a bearish technical signal. The company shows strong revenue growth to $87.49 billion in 2025, but profitability remains elusive with a net loss of $15.57 billion. Analyst sentiment is mixed with a 54% buy rating, while recent news highlights delivery growth amid a challenging EV market.

NIO's outlook hinges on achieving profitability amid fierce competition. The stock offers potential for recovery if cost controls improve and deliveries accelerate, but risks include persistent losses, high debt, and macroeconomic pressures in China. Investor patience is required given the long path to sustained earnings.